Pathologic concordance between prostate biopsy and radical prostatectomy improves with use of a novel robotic-assisted transperineal fusion biopsy platform. Optimization of risk stratification at ...
The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...
Morning Overview on MSN
Study finds microplastics in 90% of prostate cancer tumors
Researchers at NYU Langone Health have detected tiny plastic fragments in nine out of 10 prostate cancer tumors examined, a ...
Investigators sought to determine the effect of “Smart PSA” guidelines on screening behavior and biopsy outcomes among Black men.
URO-1, Inc. is a life sciences company dedicated to advancing the tools and workflows used in soft tissue biopsy diagnostics.
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...
The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...
GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...
Blood tests are the most common way for health professionals to detect and diagnose a range of medical conditions. But can it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results